

5 May 2009

Listing of a new brand of Metoprolol Succinate (Metoprolol-AFT CR) in the Pharmaceutical Schedule

PHARMAC is pleased to announce the listing of a new brand of metoprolol succinate sustained release tablet (Metoprolol-AFT CR) on the Pharmaceutical Schedule from 1 June 2009.

Details of the Decision

Metoprolol-AFT CR will be listed in Section B and Part II of Section H of the Pharmaceutical Schedule at the following prices and subsidies from 1 June 2009 (ex-manufacturer, excluding GST):

Brand	Strength	Pack Size	Price and subsidy
Metoprolol-AFT CR	23.75 mg	30	\$2.73
Metoprolol-AFT CR	47.5 mg	30	\$3.41
Metoprolol-AFT CR	95 mg	30	\$5.88
Metoprolol-AFT CR	190 mg	30	\$10.63

Metoprolol-AFT CR will be fully funded for all patients (the current metoprolol succinate endorsement criteria will not apply to Metoprolol-AFT CR).

Feedback Received regarding the Proposal

The listing of Metoprolol-AFT CR was the subject of a consultation letter dated 21 June 2007. We appreciated the feedback that was received as a result of this consultation and acknowledge the time that people took to respond.

The consultation document noted that, at the time of the consultation, Metoprolol-AFT CR was not registered and that the listing was subject to the necessary consents being obtained. We can confirm that the necessary consents have been obtained and that Metoprolol-AFT CR is approved for use in New Zealand.

More information

If you have any queries about these changes please contact the PHARMAC helpline on 0800 66 00 50 (9 am to 5 pm weekdays).